Kobho GLP price, composition and full pharmacy review
Kobho GLP is a dual food supplement (vials + capsules) with Berbevis® phytosomed berberine as its main active — an adjunct for mild to moderate excess weight, not a substitute for Ozempic or for lifestyle change. This is my 2026 pharmacist analysis of the 30-vial + 90-capsule pack: real composition, mechanism of action, who it fits, correct regimen and realistic expectations without misleading marketing.
Quick summary:
- What it is: dual food supplement (vial + capsule) for 30 days.
- Main active: Berbevis® phytosomed berberine (better oral bioavailability than free berberine).
- Cofactors: calcium butyrate + polyphenols (EGCG, resveratrol, chlorogenic acid) + fucoxanthin + forskolin + chromium + ginseng + spirulina.
- Who for: mild to moderate excess weight (BMI 25–30) alongside real changes in diet and exercise.
- Non‑negotiable: does not replace Ozempic or genuine lifestyle change. It is an adjunct, not the engine. Visible effect in 8–12 weeks.
What Kobho GLP is and how the product is positioned
Kobho GLP is a dual food supplement from the Spanish pharmacy brand Kobho, designed as metabolic support during weight management. It is NOT a medicine and does NOT contain synthetic GLP‑1 analogues — it is a combination of actives that may influence mechanisms related to the AMPK pathway and insulin sensitivity.
- Dual format with pharmaceutical logic: 30 drinkable vials (water‑soluble extracts with faster absorption) + 90 capsules (actives sensitive to oxidation with more controlled release with each meal).
- Duration: 30 days per full pack. There are double (60‑day) and triple (90‑day) formats with a better price per dose.
- Legal category: food supplement, not a medicine. No prescription or mandatory medical follow‑up required, but do seek advice if you take long‑term medication.
- Honest positioning: adjunct to lifestyle change, not a replacement for prescription GLP‑1 medicines (Ozempic, Wegovy, Mounjaro).
Real composition of Kobho GLP: active by active
I go ingredient by ingredient as I do in the pharmacy — some actives have stronger evidence than others:
- Phytosomed berberine (Berbevis®): the best‑supported active. A 2019 meta‑analysis in Frontiers in Pharmacology including 27 trials shows significant reductions in fasting glucose, HbA1c and triglycerides. The phytosome form improves oral bioavailability (free berberine is poorly absorbed). Mechanism mainly via AMPK activation.
- Calcium butyrate: provides butyrate (a short‑chain fatty acid) for the intestinal mucosa and microbiota. Growing evidence around insulin sensitivity.
- Green tea polyphenols (EGCG), resveratrol and chlorogenic acid: antioxidant triad with studies on lipid and glucose metabolism.
- Fucoxanthin (brown seaweed) and forskolin (Coleus forskohlii): actives with interesting preliminary evidence on body composition in overweight.
- Trivalent chromium: the only ingredient here with an authorised EFSA health claim (Reg. 432/2012) for normal macronutrient metabolism and maintenance of normal blood glucose levels.
- Ginseng and spirulina: contribute to the overall energy‑nutritional profile.
My honest conclusion: Berbevis® and trivalent chromium are the most strongly supported. The other actives add complementary mechanisms on microbiota, oxidation and lipid metabolism. As a whole it makes sense as support within a broader strategy, not as a substitute for lifestyle change or prescribed medical treatment.
How Kobho GLP works in the body
The mechanism is indirect — Kobho GLP does not provide synthetic GLP‑1 but actives that modulate related pathways:
- AMPK pathway (berberine): improves muscular glucose uptake, inhibits hepatic fat synthesis and stimulates endogenous GLP‑1 secretion from L cells.
- Butyrate + microbiota: short‑chain fatty acids act on receptors on L cells, indirectly enhancing GLP‑1.
- Antioxidant polyphenols: reduce low‑grade inflammation and oxidative stress, both involved in insulin resistance.
- Magnitude: endogenous GLP‑1 increase of around 20–35% with berberine over 8–12 weeks — far below prescription medicines.
Who Kobho GLP is for (and who it is not for)
The most frequent issue I see at the counter is people arriving expecting Kobho GLP to behave like a prescription medicine. Clear coordinates to help you decide:
- A good fit: adult with mild to moderate excess weight (BMI 25–30), fasting glucose at the higher end of normal, tendency to snacking or sweets, willing to make real changes in diet and exercise.
- A supportive option: perimenopause with early metabolic syndrome features, documented prediabetes, someone already exercising who wants to fine‑tune metabolism.
- NOT suitable on its own: severe obesity (BMI >35 needs multidisciplinary medical management), type 2 diabetes without supervision, pregnancy or breastfeeding, severe liver or kidney disease, expectation of effects comparable to Ozempic/Wegovy.
- Key question before buying: are you making real changes in food choices and activity? If the answer is no, no supplement will compensate for that.
How to take Kobho GLP correctly
The general regimen for the pack (always check the leaflet of your specific batch):
- Morning on an empty stomach or light breakfast: 1 drinkable vial. The water‑soluble extracts (polyphenols, fucoxanthin, forskolin) absorb better with little gastric content.
- With each main meal: 1 capsule (3 per day in total). The aim is the effect on postprandial glucose provided by phytosomed berberine and chromium at the time of each meal.
- Hydration: 1.5–2 litres of water per day. This helps digestive tolerance of berberine and supports butyrate's effect on the intestinal mucosa.
- Duration: 3 consecutive months then review weight, fasting glucose and appetite sensations. Double/triple packs are designed for full courses with a better price per day.
- Initial tolerance: during the first days with berberine you may notice mild digestive discomfort (wind, looser stools) which usually settles before day 10.
Realistic expectations: what it can and cannot do
This is what Kobho GLP can reasonably contribute within a wider plan:
- Smoother appetite control: fewer cravings between meals, slightly longer satiety. It does NOT cause dramatic weight loss.
- Support for postprandial glucose: chromium + berberine can shift fasting glucose and triglycerides in a statistically significant way after ≥8 weeks in people whose baseline markers are raised.
- A stabiliser for the first months: helps you build new habits. The engine of change remains diet and physical activity, not the supplement itself.
- What will NOT happen: meaningful weight loss without dietary and activity changes, nor the intense appetite reduction seen with semaglutide acting on central GLP‑1 receptors.
- No trials replicating medicines: no randomised controlled trial has shown that any "GLP‑1 activator" supplement reproduces outcomes of prescription agonists. If someone promises that, it is advertising rather than evidence.
Contraindications and when to seek advice first
Kobho GLP is not risk‑free. These situations need prior assessment:
- Absolute contraindications: pregnancy and breastfeeding (no safety data), type 1 diabetes, active eating disorders, under‑18s.
- You must seek advice if you take long‑term medicines: berberine interacts with ciclosporin, metformin, anticoagulants and some antibiotics.
- Type 2 diabetes on oral antidiabetics: risk of hypoglycaemia due to additive effect. Glucose monitoring and dose adjustment under medical supervision are essential.
- Severe liver or kidney disease: medical assessment first because berberine and polyphenols may have prolonged metabolism.
- Persistent digestive symptoms: if wind or loose stools continue beyond the initial 2 weeks, stop taking it and seek advice.
Kobho GLP makes sense as support within a genuine lifestyle change plan and in the right profile (BMI 25–30 without a clear indication for medicines). Outside that profile, the appropriate route is medical assessment for GLP‑1 prescription medicines or professional consultation. You can also read my comparative guide to pharmacy GLP‑1 supplements.
Kobho GLP composition: ingredients and evidence
| Ingredient | Proposed mechanism | Level of evidence | EFSA claim |
|---|---|---|---|
| Phytosomed berberine (Berbevis®) | AMPK activation, improved insulin sensitivity, control of postprandial glucose | Moderate (meta-analyses) | Not authorised — regulatory grey area in EU |
| Calcium butyrate | Intestinal mucosal health, microbiota, insulin sensitivity | Emerging (in vitro / preclinical) | Not authorised |
| EGCG (epigallocatechin gallate) — green tea | Antioxidant action, lipid metabolism | Preliminary | Not authorised for metabolism |
| Resveratrol | Antioxidant action, mitochondrial support | Preliminary | Not authorised |
| Chlorogenic acid — green coffee | Blunting of postprandial glycaemic spikes | Preliminary | Not authorised |
| Fucoxanthin — brown seaweed | Body composition in overweight | Preliminary (small studies) | Not authorised |
| Forskolin — Coleus forskohlii | Adenylate cyclase activation, lipolysis | Preliminary | Not authorised |
| Trivalent chromium | Macronutrient metabolism, normal blood glucose | Moderate | Yes — Regulation 432/2012 |
| Ginseng | Energy support and performance | Traditional / Preliminary | Not authorised for metabolism |
| Spirulina | Nutritional contribution, antioxidant | Well documented nutritionally | Yes — source of protein |
Frequently asked questions
Scientific references
